Analysts’ Viewpoint
Increase in incidence of lung cancer, especially in developing countries, is the key driver of the global lung cancer diagnostics market. Surge in awareness about the importance of early and accurate diagnosis of the cancer is expected to accelerate industry development. Technological advancements in diagnostic technology, such as development of non-invasive diagnostic methods and discovery of new biomarkers, are anticipated to offer lucrative opportunities to market players.
High cost of diagnostic tests is a key market restraint. Availability of alternative diagnostic methods that are more accessible and cost-effective is also projected to hamper market progress. Manufacturers are investing significantly in R&D of new and improved diagnostic methods to increase their market share.
Lung cancer is a type of cancer that originates in the lungs and affects the cells lining the air passages. It is the leading cause of cancer deaths globally, accounting for over 1.7 million deaths each year. The two primary types of lung cancer are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
Early detection and treatment of lung cancer plays a crucial role in increasing the chances of survival. Treatment options include surgery, radiation therapy, chemotherapy, and targeted therapy. The choice of treatment depends on the type and stage of the cancer, as well as the patient's overall health. Various diagnostic tests and technologies are used to detect and diagnose lung cancer. Common diagnostic methods are chest X-ray, CT scan, PET scan, biopsy, and blood test.
Increase in incidence of lung cancer and advancements in diagnostic technology are driving market statistics. Rise in demand for early and accurate diagnosis is projected to bolster industry growth in the next few years. However, high cost, shortage of trained personnel, and lack of access to diagnostic services in developing countries are anticipated to restrain the market in the near future.
Surge in prevalence of lung cancer is driving global lung cancer diagnostics market growth. Lung cancer is the second most common cancer in both men and women in the U.S., with an estimated 228,820 new cases and 135,720 deaths in 2021. The five-year survival rate for lung cancer is only 18%, which is lower than that for many other types of cancer.
Increase in incidence of lung cancer across the globe is expected to propel the demand for effective and accurate diagnostic tests. Early and accurate diagnosis helps increase the chances of survival. This has led to the development and growth of advanced diagnostic techniques.
Technological advancements are projected to propel the global lung cancer diagnostics market size during the forecast period. Development of new and innovative diagnostic technologies has improved the accuracy and efficiency of lung cancer diagnosis. For instance, usage of non-invasive diagnostic methods, such as CT scans and PET scans, has significantly improved the early detection of lung cancer.
Advances in imaging technology have led to the development of more sensitive and accurate imaging techniques, such as low-dose CT scans, which can detect smaller and earlier stage tumors.
Development of new and innovative biomarkers for early detection of lung cancer is also augmenting market dynamics. Usage of these biomarkers in blood tests, such as liquid biopsy, has improved the accuracy and efficiency of lung cancer diagnosis and created new opportunities for the development of personalized medicine.
In terms of diagnostic test, the imaging tests segment accounted for the largest global lung cancer diagnostics market share in 2021. Imaging tests, such as chest X-rays, CT scans, and PET scans, are widely used for the detection and diagnosis of lung cancer. These tests provide visual images of chest and lungs, enabling healthcare professionals to identify and assess size, location, and stage of any tumor.
Recent advancements in imaging technology, such as development of low-dose CT scans and improved accuracy of PET scans, have increased the efficiency and effectiveness of imaging tests in detecting and diagnosing lung cancer. Increase in demand for early & accurate diagnosis and advancements in imaging technology have contributed to the growth of the imaging tests segment.
Based on cancer type, the non-small cell lung cancer (NSCLC) segment led the global lung cancer diagnostics market in 2021. NSCLC is the most common type of lung cancer, accounting for 80% to 85% of all lung cancer cases. Rise in prevalence of NSCLC and increase in demand for early & accurate diagnosis have led to a surge in usage of diagnostic tests for non-small cell lung cancer diagnosis.
Advancements in diagnostic technology, such as development of non-invasive diagnostic methods and discovery of new biomarkers, is contributing to segment growth. The NSCLC segment is expected to account for significant market share in the next few years. This can be ascribed to the rise in prevalence of NSCLC and continued advancements in diagnostic technology.
In terms of end-user, the hospitals segment held significant share of the global lung cancer diagnostics market in 2021. Hospitals are the primary healthcare settings for lung cancer diagnosis and treatment. These settings have the necessary equipment, facilities, and trained personnel to perform advanced diagnostic tests and treatments for lung cancer.
Rise in prevalence of lung cancer and increase in demand for early & accurate diagnosis have led to a surge in demand for lung cancer diagnostic services in hospitals. Advancements in diagnostic technology, such as the development of non-invasive diagnostic methods, have increased the demand for these services in hospitals.
Hospitals are equipped with advanced imaging technology and trained personnel to perform imaging tests, such as CT scans and PET scans, which play a vital role in the diagnosis of lung cancer.
As per global lung cancer diagnostics market trends, Europe held significant market share in 2021. This can be ascribed to high incidence of lung cancer, advanced healthcare infrastructure, and presence of leading players in the region.
North America accounted for the second-largest share in 2021. High incidence of lung cancer and presence of advanced healthcare systems are augmenting the market in the region.
The market in Asia Pacific is expected to witness significant growth in the next few years, driven by the rise in prevalence of lung cancer and increase in demand for early and accurate diagnosis. Surge in demand for advanced diagnostic services in developing countries, such as China and India, is expected to contribute to market growth in Asia Pacific.
The market in Latin America and Middle East & Africa is likely to experience moderate growth in the next few years. This can be ascribed to the increase in demand for advanced diagnostic services and rise in awareness about the importance of early and accurate diagnosis in these regions.
Expansion of product portfolio and mergers & acquisitions are key strategies adopted by prominent manufacturers in the global lung cancer diagnostics market. Abbott, Amoy Diagnostics Co., Bio-Rad Laboratories, Inc., Boditech Med, Inc., Danaher, F. Hoffmann-La Roche Ltd., INOVIQ, MedGenome, Oncocyte Corporation, QIAGEN, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., Illumina, Biodesix, and Paige AI, Inc. are the leading players in the global lung cancer diagnostics market.
The lung cancer diagnostics market report profiles key players based on parameters such as company overview, financial overview, strategies, portfolio, segments, and recent developments.
|
Attribute |
Detail |
|
Size in 2022 |
US$ 14.1 Bn |
|
Forecast (Value) in 2031 |
More than US$ 26.3 Bn |
|
Growth Rate (CAGR) |
7.3% |
|
Forecast Period |
2023–2031 |
|
Historical Data Available for |
2017–2021 |
|
Quantitative Units |
US$ Bn for Value |
|
Market Analysis |
It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global industry was valued at US$ 14.1 Bn in 2022
It is projected to reach more than US$ 26.3 Bn by 2031
The CAGR is anticipated to be 7.3% from 2023 to 2031
Rise in incidence of lung cancer and technological advancements in lung cancer diagnostics
North America is projected to account for significant share during the forecast period
Abbott, Amoy Diagnostics Co., Bio-Rad Laboratories, Inc., Boditech Med, Inc., Danaher, F. Hoffmann-La Roche Ltd., INOVIQ, MedGenome, Oncocyte Corporation, QIAGEN, Quest Diagnostics Incorporated, Thermo Fisher Scientific, Inc., Biodesix, and Paige AI, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lung Cancer Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Lung Cancer Diagnostics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Technological Advancements
5.2. Lung Cancer Statistics: Incidence and Mortality rate
5.3. Regulatory Scenario by Region/Globally
5.4. COVID-19 Impact Analysis
6. Global Lung Cancer Diagnostics Market Analysis and Forecast, by Diagnostic Test
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Diagnostic Test, 2017–2031
6.3.1. Imaging Tests
6.3.2. Pulmonary Function Tests
6.3.3. Lung Tissue Analysis
6.3.4. Others
6.4. Market Attractiveness Analysis, by Diagnostic Test
7. Global Lung Cancer Diagnostics Market Analysis and Forecast, by Cancer Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Cancer Type, 2017–2031
7.3.1. Non-small Cell Lung Cancer (NSCLC)
7.3.2. Small Cell Lung Cancer (SCLC)
7.4. Market Attractiveness Analysis, by Cancer Type
8. Global Lung Cancer Diagnostics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Clinics
8.3.3. Diagnostic Centers
8.4. Market Attractiveness Analysis, by End-user
9. Global Lung Cancer Diagnostics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Lung Cancer Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Diagnostic Test, 2017–2031
10.2.1. Imaging Tests
10.2.2. Pulmonary Function Tests
10.2.3. Lung Tissue Analysis
10.2.4. Others
10.3. Market Value Forecast, by Cancer Type, 2017–2031
10.3.1. Non-small Cell Lung Cancer (NSCLC)
10.3.2. Small Cell Lung Cancer (SCLC)
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Diagnostic Centers
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Diagnostic Test
10.6.2. By Cancer Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Lung Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Diagnostic Test, 2017–2031
11.2.1. Imaging Tests
11.2.2. Pulmonary Function Tests
11.2.3. Lung Tissue Analysis
11.2.4. Others
11.3. Market Value Forecast, by Cancer Type, 2017–2031
11.3.1. Non-small Cell Lung Cancer (NSCLC)
11.3.2. Small Cell Lung Cancer (SCLC)
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Diagnostic Centers
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Diagnostic Test
11.6.2. By Cancer Type
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Lung Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Diagnostic Test, 2017–2031
12.2.1. Imaging Tests
12.2.2. Pulmonary Function Tests
12.2.3. Lung Tissue Analysis
12.2.4. Others
12.3. Market Value Forecast, by Cancer Type, 2017–2031
12.3.1. Non-small Cell Lung Cancer (NSCLC)
12.3.2. Small Cell Lung Cancer (SCLC)
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Diagnostic Centers
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Diagnostic Test
12.6.2. By Cancer Type
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Lung Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Diagnostic Test, 2017–2031
13.2.1. Imaging Tests
13.2.2. Pulmonary Function Tests
13.2.3. Lung Tissue Analysis
13.2.4. Others
13.3. Market Value Forecast, by Cancer Type, 2017–2031
13.3.1. Non-small Cell Lung Cancer (NSCLC)
13.3.2. Small Cell Lung Cancer (SCLC)
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Diagnostic Centers
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of LATAM
13.6. Market Attractiveness Analysis
13.6.1. By Diagnostic Test
13.6.2. By Cancer Type
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Lung Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Diagnostic Test, 2017–2031
14.2.1. Imaging Tests
14.2.2. Pulmonary Function Tests
14.2.3. Lung Tissue Analysis
14.2.4. Others
14.3. Market Value Forecast, by Cancer Type, 2017–2031
14.3.1. Non-small Cell Lung Cancer (NSCLC)
14.3.2. Small Cell Lung Cancer (SCLC)
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Clinics
14.4.3. Diagnostic Centers
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Diagnostic Test
14.6.2. By Cancer Type
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Abbott
15.3.1.1. Company Overview
15.3.1.2. Diagnostic Test Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Amoy Diagnostics Co.
15.3.2.1. Company Overview
15.3.2.2. Diagnostic Test Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Bio-Rad Laboratories, Inc.
15.3.3.1. Company Overview
15.3.3.2. Diagnostic Test Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Boditech Med, Inc.
15.3.4.1. Company Overview
15.3.4.2. Diagnostic Test Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Danaher
15.3.5.1. Company Overview
15.3.5.2. Diagnostic Test Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. F. Hoffman La Roche
15.3.6.1. Company Overview
15.3.6.2. Diagnostic Test Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. INOVIQ
15.3.7.1. Company Overview
15.3.7.2. Diagnostic Test Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. MedGenome
15.3.8.1. Company Overview
15.3.8.2. Diagnostic Test Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Oncocyte Corporation
15.3.9.1. Company Overview
15.3.9.2. Diagnostic Test Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. QIAGEN
15.3.10.1. Company Overview
15.3.10.2. Diagnostic Test Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Quest Diagnostics Incorporated
15.3.11.1. Company Overview
15.3.11.2. Diagnostic Test Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Thermo Fisher Scientific, Inc.
15.3.12.1. Company Overview
15.3.12.2. Diagnostic Test Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. Paige AI, Inc.
15.3.13.1. Company Overview
15.3.13.2. Diagnostic Test Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
15.3.14. Biodesix
15.3.14.1. Company Overview
15.3.14.2. Diagnostic Test Portfolio
15.3.14.3. SWOT Analysis
15.3.14.4. Financial Overview
15.3.14.5. Strategic Overview
List of Tables
Table 01: Global Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Diagnostic Test, 2017–2031
Table 02: Global Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 03: Global Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 04: Global Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 05: North America Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 06: North America Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Diagnostic Test, 2017–2031
Table 07: North America Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 08: North America Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 09: Europe Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 10: Europe Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Diagnostic Test, 2017–2031
Table 11: Europe Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 12: Europe Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Asia Pacific Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Asia Pacific Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Diagnostic Test, 2017–2031
Table 15: Asia Pacific Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 16: Asia Pacific Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 17: Latin America Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 18: Latin America Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Diagnostic Test, 2017–2031
Table 19: Latin America Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 20: Latin America Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Middle East & Africa Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Middle East & Africa Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Diagnostic Test, 2017–2031
Table 23: Middle East & Africa Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 24: Middle East & Africa Lung Cancer Diagnostics Market Size (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Lung Cancer Diagnostics Market Size (US$ Mn) and Distribution (%), by Region, 2022 and 2031
Figure 02: Global Lung Cancer Diagnostics Market Revenue (US$ Mn), by Diagnostic Test, 2022
Figure 03: Global Lung Cancer Diagnostics Market Value Share, by Diagnostic Test, 2022
Figure 04: Global Lung Cancer Diagnostics Market Revenue (US$ Mn), by Cancer Type, 2022
Figure 05: Global Lung Cancer Diagnostics Market Value Share, by Cancer Type, 2022
Figure 06: Global Lung Cancer Diagnostics Market Revenue (US$ Mn), by End-user, 2022
Figure 07: Global Lung Cancer Diagnostics Market Value Share, by End-user, 2022
Figure 08: Global Lung Cancer Diagnostics Market Value Share, by Region, 2022
Figure 09: Global Lung Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 10: Global Lung Cancer Diagnostics Market Value Share Analysis, by Diagnostic Test, 2022 and 2031
Figure 11: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2023-2031
Figure 12: Global Lung Cancer Diagnostics Market Value Share Analysis, by Cancer Type, 2022 and 2031
Figure 13: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2023-2031
Figure 14: Global Lung Cancer Diagnostics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 15: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 16: Global Lung Cancer Diagnostics Market Value Share Analysis, by Region, 2022 and 2031
Figure 17: Global Lung Cancer Diagnostics Market Attractiveness Analysis, by Region, 2023-2031
Figure 18: North America Lung Cancer Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 19: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by Country, 2017–2031
Figure 20: North America Lung Cancer Diagnostics Market Value Share Analysis, by Country, 2022 and 2031
Figure 21: North America Lung Cancer Diagnostics Market Value Share Analysis, by Diagnostic Test, 2022 and 2031
Figure 22: North America Lung Cancer Diagnostics Market Value Share Analysis, by Cancer Type, 2022 and 2031
Figure 23: North America Lung Cancer Diagnostics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 24: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2023–2031
Figure 25: North America Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2023–2031
Figure 26:North America Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2023-2031
Figure 27: Europe Lung Cancer Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 28: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 29: Europe Lung Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 30: Europe Lung Cancer Diagnostics Market Value Share Analysis, by Diagnostic Test, 2022 and 2031
Figure 31: Europe Lung Cancer Diagnostics Market Value Share Analysis, by Cancer Type, 2022 and 2031
Figure 32: Europe Lung Cancer Diagnostics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 33: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2023–2031
Figure 34: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2023–2031
Figure 35: Europe Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 36: Asia Pacific Lung Cancer Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 37: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 38: Asia Pacific Lung Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 39: Asia Pacific Lung Cancer Diagnostics Market Value Share Analysis, by Diagnostic Test, 2022 and 2031
Figure 40: Asia Pacific Lung Cancer Diagnostics Market Value Share Analysis, by Cancer Type, 2022 and 2031
Figure 41: Asia Pacific Lung Cancer Diagnostics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 42: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2023–2031
Figure 43: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2023–2031
Figure 44: Asia Pacific Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 45: Latin America Lung Cancer Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 46: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 47: Latin America Lung Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 48: Latin America Lung Cancer Diagnostics Market Value Share Analysis, by Diagnostic Test, 2022 and 2031
Figure 49: Latin America Lung Cancer Diagnostics Market Value Share Analysis, by Cancer Type, 2022 and 2031
Figure 50: Latin America Lung Cancer Diagnostics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 51: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2023–2031
Figure 52: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2023–2031
Figure 53: Latin America Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2023–2031
Figure 54: Middle East & Africa Lung Cancer Diagnostics Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 55: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2017–2031
Figure 56: Middle East & Africa Lung Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 57: Middle East & Africa Lung Cancer Diagnostics Market Value Share Analysis, by Diagnostic Test, 2022 and 2031
Figure 58: Middle East & Africa Lung Cancer Diagnostics Market Value Share Analysis, by Cancer Type, 2022 and 2031
Figure 59: Middle East & Africa Lung Cancer Diagnostics Market Value Share Analysis, by End-user, 2022 and 2031
Figure 60: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by Diagnostic Test, 2023–2031
Figure 61: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by Cancer Type, 2023–2031
Figure 62: Middle East & Africa Lung Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Lung Cancer Diagnostics Market
*86 figures and 60 tables includes